Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 2.2 EX-2.2
- 4.19 EX-4.19
- 5.1 EX-5.1
- 8.1 EX-8.1
- 8.2 EX-8.2
- 10.48 EX-10.48
- 10.49 EX-10.49
- 21.1 EX-21.1
- 23.3 EX-23.3
- 23.4 EX-23.4
- 23.5 EX-23.5
- 24.2 EX-24.2
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- Download Excel data file
- View Excel data file
Associated filings
- 24 Mar 21 EFFECT Notice of effectiveness
- 23 Mar 21 424B3 Prospectus supplement
-
19 Mar 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Jan 21 S-4 Registration of securities issued in business combination transactions
TNFA similar filings
Filing view
External links
Exhibit 99.6
Consent of Proposed Director
I, Jude Uzonwanne, hereby consent to the following:
● | to serve as a director of Akers Biosciences, Inc. if the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated November 11, 2020, by and among Akers Biosciences, Inc., XYZ Merger Sub, Inc. and MyMD Pharmaceuticals, Inc. are consummated, including the merger of MyMD Pharmaceuticals, Inc. with and into XYZ Merger Sub, Inc., with MyMD Pharmaceuticals, Inc. continuing as the surviving corporation (the “Merger”); | |
● | to be named as a proposed director of Akers Biosciences, Inc. in the Registration Statement on Form S-4, including the joint proxy and consent solicitation statement/prospectus, to be filed by Akers Biosciences, Inc. in connection with the Merger, and in any and all amendments and supplements thereto (collectively, the “Registration Statement”); and | |
● | to the filing of this consent as an exhibit to the Registration Statement. |
![]() | Date: | 01/09/2021 | |
Jude Uzonwanne |